Consolidated Statements of Operations and Comprehensive Loss - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Revenues | |||
| Total net sales | $ 551,102,000 | $ 572,458,000 | $ 627,598,000 |
| Cost of revenues | |||
| Total cost of sales | 323,816,000 | 315,642,000 | 360,574,000 |
| Gross profit | 227,286,000 | 256,816,000 | 267,024,000 |
| Operating expenses | |||
| Research and development, net | 77,304,000 | 99,142,000 | 94,425,000 |
| Selling, general and administrative | 222,471,000 | 243,335,000 | 260,179,000 |
| Total operating expenses | 299,775,000 | 342,477,000 | 354,604,000 |
| Operating loss | (72,489,000) | (85,661,000) | (87,580,000) |
| Financial income (expenses), net | 10,386,000 | 1,676,000 | 2,993,000 |
| Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total | (62,103,000) | (83,985,000) | (84,587,000) |
| Income tax benefit (expenses) | 3,082,000 | 2,973,000 | 5,782,000 |
| Share in net profits (losses) of associated companies | 39,100,000 | 33,325,000 | 32,705,000 |
| Net loss | $ (104,285,000) | $ (120,283,000) | $ (123,074,000) |
| Earnings Per Share, Basic | $ (1.28) | $ (1.70) | $ (1.79) |
| Weighted average shares outstanding - basic and diluted (in Shares) | 81,602,000 | 70,858,000 | 68,666,000 |
| Comprehensive Loss | |||
| Net loss | $ (104,285,000) | $ (120,283,000) | $ (123,074,000) |
| Other comprehensive income (loss), net of tax: | |||
| Foreign currency translation adjustments | 7,365,000 | (4,069,000) | 3,650,000 |
| Unrealized gains (losses) on derivatives designated as cash flow hedge | (5,531,000) | 3,117,000 | 2,089,000 |
| Other comprehensive income (loss) | 1,834,000 | (952,000) | 5,739,000 |
| Comprehensive loss | (102,451,000) | (121,235,000) | (117,335,000) |
| Products | |||
| Revenues | |||
| Total net sales | 380,269,000 | 391,917,000 | 433,741,000 |
| Cost of revenues | |||
| Total cost of sales | 206,475,000 | 197,807,000 | 226,510,000 |
| Services | |||
| Revenues | |||
| Total net sales | 170,833,000 | 180,541,000 | 193,857,000 |
| Cost of revenues | |||
| Total cost of sales | $ 117,341,000 | $ 117,835,000 | $ 134,064,000 |
| X | ||||||||||
- Definition Unrealized Gains (Losses) On Derivatives Designated As Cash Flow Hedge No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of other comprehensive income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|